![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Background:
Ivabradine, a specific heart rate lowering agent, was shown in the SHIFT study to reduce time to first hospitalization for worsening heart failure (HF) in chronic systolic HF patients and also to reduce recurrent/total hospitalizations over the study interval. We assessed the effects of adding ivabradine in patients with systolic HF on the number needed to treat (NNT) to reduce recurrent hospitalizations.
Methods:
The SHIFT trial included 6505 patients with symptomatic HF (NYHA II–IV), left ventricular ejection fraction ≤35% and heart rate ≥70 bpm in sinus rhythm. Patients were randomized to either ivabradine or placebo in addition to guidelines-based drug therapy. The times to first hospitalization were analyzed using a univariate Cox proportional-hazards model; the associated NNT was calculated using Kaplan–Meier estimates of the time-to-event curves at 1 year in each treatment arm. Recurrent hospitalizations were analyzed using a negative binomial and the estimated annual event rates used to calculate the associated patient-time NNTs respectively.
Results:
The estimated NNT (number needed to initiate treatment with ivabradine to prevent one first HF hospitalization within 1 year) was 27 (estimated hazard ratio: 0.75, P < 0.0001). For recurrent HF hospitalizations, one event would be prevented on average per 14 patient-years for any year of follow-up over the course of SHIFT (estimated rate ratio: 0.71, P < 0.0001). A key limitation of this analysis is that it did not account for a relationship between recurrent HF hospitalizations and subsequent mortality.
Conclusion:
In chronic systolic HF the effect of ivabradine on reducing recurrent HF hospitalizations results in a lower NNT compared to the effect on the time for first hospitalization. The effect of ivabradine on recurrent hospitalizations, in addition to first events, may be a more appropriate measure when considering the impact of a treatment with ivabradine on healthcare resource utilization.
Transparency
Declaration of funding
Amgen sponsored this analysis of the SHIFT dataset and were responsible for paying the FastTrack fees.
Author contributions: All authors contributed to ICMJE criteria a, b, c and d.
Declaration of financial/other relationships
J.K.R. has disclosed that she received sponsorship from Amgen to carry out the analysis. This report is independent research arising from a Post-Doctoral Fellowship (J.K.R., PDF-2013-06-024) supported by the National Institute for Health Research. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. A.K. has disclosed that he is an employee of Amgen. J.S.B. has disclosed that he is a consultant/advisor to Servier, Amgen, Novartis, Pfizer, Cardiorentis, ARMGO, Takeda USA, Celladon and AstraZeneca and is a stock shareholder in BioMARIN. I.F. has disclosed that he has received research grants from Servier and Amgen and is a consultant/advisor to Amgen and Servier. S.J.P. has disclosed that he is a consultant/advisor to Amgen.
Acknowledgments
No assistance in the preparation of this article is to be declared.